Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIMPLE Chemotherapy for NK/T Cell Malignancies
NCT03623087Phase 3Unknown
- Sponsor
- The University of Hong Kong
- Start
- Jul 2017
- Primary completion
- Mar 2020
- Modality
- Orthosteric Ligands, Replacement Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of cisplatin, gemcitabine, ifosfamide, etoposide, asparaginase escherichia coli in Extranodal NK/T-cell lymphoma (ENKTL), aggressive natural killer cell leukemia (ANKL), sponsored by The University of Hong Kong. Status: unknown.
02
Drugs
cisplatingemcitabineifosfamideetoposideasparaginase escherichia coli
03
Conditions
Extranodal NK/T-cell lymphoma (ENKTL)aggressive natural killer cell leukemia (ANKL)
Beyond the preview
Go deeper on NCT03623087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03623087.